ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IMM Immupharma Plc

1.15
-0.005 (-0.43%)
13 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.005 -0.43% 1.15 1.02 1.255 1.27 1.27 1.27 733,994 16:35:03
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Finance Services 0 -2.92M -0.0070 -1.81 4.81M
Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 1.16p. Over the last year, Immupharma shares have traded in a share price range of 0.83p to 2.90p.

Immupharma currently has 416,440,000 shares in issue. The market capitalisation of Immupharma is £4.81 million. Immupharma has a price to earnings ratio (PE ratio) of -1.81.

Immupharma Share Discussion Threads

Showing 39151 to 39173 of 39200 messages
Chat Pages: 1568  1567  1566  1565  1564  1563  1562  1561  1560  1559  1558  1557  Older
DateSubjectAuthorDiscuss
14/8/2024
10:07
So keep your money in your pocket then Nobby 😎
socionomics
14/8/2024
09:57
Well the chart shows the price is most definitely in a long term downtrend and short term is in the middle of a trading range. That does not indicate a rise is imminent to me….
nobbygnome
14/8/2024
09:30
Not everyone who picks up a paintbrush is a Picasso.
socionomics
14/8/2024
09:05
I think the gerbil is likely to do better as it isn't subject to your biases.
supernumerary
14/8/2024
07:11
All of which just goes to show how pointless it is to rely on charts.

Two posters here manage to draw very different conclusions from the exact same graph.

A graph, at that, which is backwards-looking.

You might as well ask your pet gerbil to forecast.

lord loads of lolly
14/8/2024
05:03
Thanks for the reply….but I absolutely don’t see that. From my view the price is in the middle of a trading range and could go either way….
nobbygnome
13/8/2024
20:56
Nobby, so far as I can ascertain on charting, the share price is sitting right on the resistance / support level. If it rises the top of the trading range will be 2.5 p. In candle chart, it is a white candle (rising) so I am inclined to say that it will rise to 2.5 p in the next cycle.
kingston78
13/8/2024
19:35
The current chart looks poor to me; I certainly wouldn’t buy after glancing at it!

Please explain why you think it’s positive….

nobbygnome
13/8/2024
19:21
That's because they only tell you what's already happened.
supernumerary
13/8/2024
17:46
Wait and see fellas. The charts never lie.
socionomics
13/8/2024
14:05
Thanks Nobby - much appreciated.No logical reason why there should be any upward movement of the share price in the near future then.Time to go back to sleep
husbod
12/8/2024
15:40
Well they haven’t even submitted the IND for the CIDP indication so that’s ages away from starting. As for SLE, well that’s down to Avion. It’s always been a concern of mine that Avion have no experience in SLE. It’s a very complicated indication with a high placebo response, the possibility of other drugs such as steroids confounding the results and a heterogeneous range of symptoms. So clearly Avion are struggling to get it off the ground which is why it would appear that the earliest results could be out is 2027. Of course we haven’t seen the protocol yet so don’t know the length of dosing, which makes it a little difficult to predict. In addition there is dose ranging incorporated in the design which adds complexity.

So all in all it’s about as clear as mud at the moment….

nobbygnome
12/8/2024
13:17
Hi NobbyAlthough I remain a holder it's not a share I have really followed over the last couple of years so any chance you could give me a brief summary of where we are on the long delayed phase 3 approval application.Btw Socio et moi are doing quite nicely on another pharma tiddler STX, although granted it does have an FDA approved product.
husbod
12/8/2024
11:34
Oh and if I do buy I want socionomics to go into full ramp mode….although his last attempt was a pitiful failure!

Can’t complain about Incanthera though..well done Tim; you are a hero!

nobbygnome
12/8/2024
11:30
LOL at least you admit I called this exactly right!

I’m most definitely not a holder although it may be worth a punt if they ever get round to actually starting the phase III. Results in 2027 anyone….

nobbygnome
12/8/2024
11:30
Double post
nobbygnome
02/8/2024
08:10
It looks like the ramp failed….
nobbygnome
01/8/2024
17:29
Short this dog.
ken chung
01/8/2024
08:42
P3 hasn’t even started yet so difficult to know when they are due!😆
nobbygnome
01/8/2024
08:25
Nobby will know Mr P. He's the resident expert on IMM.
socionomics
31/7/2024
21:55
P3 results due?
mr pierrepoint
31/7/2024
12:58
6p minimum target. (keep 14p in the back of your mind too.)



Please note: This is just ramping. I am never right!

I just got lucky on CPX, CPI, GDR, MTRO, BT, STX, SBTX, and others, to name a few from 2024.

socionomics
31/7/2024
12:54
Yep, it's all just ramping Nobby. Nothing to see here.
socionomics
Chat Pages: 1568  1567  1566  1565  1564  1563  1562  1561  1560  1559  1558  1557  Older

Your Recent History

Delayed Upgrade Clock